Women with HER2-positive and triple-negative breast cancer have an elevated risk of developing brain metastasis regardless of active systemic treatment receipt.
The average cost during the initial phase of breast cancer care for Medicare fee-for-service beneficiaries was $28,075 – $13,344 of which went toward physician services and $7456 for outpatient services.
The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer.
A recent research letter highlights gaps in understanding among community oncology practices of the Medicare Access and CHIP Reauthorization Act Quality Payment Program.
Recently hospitalized patients with insulin-dependent type 2 diabetes experienced a significantly higher 90-day readmission risk than nondependent patients.
Student pharmacists can accurately and efficiently acquire medication histories for patients admitted to a large academic hospital, reducing the workload of the clinical staff.
More than 60% of patients prescribed antiretroviral therapy at a large community teaching hospital experienced at least one prescription error.
Heart failure, angina, and other cardiovascular adverse events occur more frequently in patients with relapsed multiple myeloma receiving a conventional therapy.
Although the ASCO Value Framework can help quantify the health value and benefit of various cancer therapies, it has essential limitations for its use in the treatment of chronic lymphocytic leukemia.
Results of a recent study showed that the prognostic implications of patient-specific and tumor biological features vary significantly across age-groups of patients with multiple myeloma.